托伐普坦治疗儿童ADPKD的两年开放标签扩展试验
这是一项针对儿童和青少年常染色体显性多囊肾病(ADPKD)的3b期研究,A阶段为1年随机安慰剂对照试验,B阶段为2年开放标签扩展。81例完成A阶段的患者进入B阶段接受托伐普坦治疗。结果显示托伐普坦安全性和生活质量良好,肾功能稳定,htTKV增长在治疗第一年最慢。
要点
- 托伐普坦在儿童ADPKD患者中安全性与总体生活质量保持良好。
- B阶段中既往安慰剂组的水利尿相关和脱水相关不良事件多于既往托伐普坦组。
- eGFR在A阶段托伐普坦组保持稳定而安慰剂组下降,B阶段两组下降斜率相似。
核心结论
- 托伐普坦相关安全性和总体健康相关生活质量在2年扩展期中保持良好,肾功能稳定。
- htTKV增长最慢出现在托伐普坦治疗的第一年。
研究设计与样本
- 3b期、两部分研究(NCT02964273):A阶段为1年随机安慰剂对照试验,B阶段为2年开放标签扩展。
- 84例完成A阶段的儿童和青少年ADPKD患者中81例进入B阶段,均接受托伐普坦,按体重和耐受性滴定。
主要发现
- 两阶段均未观察到符合药物性肝损伤标准的肝酶升高。
- B阶段中既往安慰剂组的水利尿相关不良事件发生率为48.7%,既往托伐普坦组为14.3%;脱水相关不良事件分别为28.2%和14.3%。
- A阶段eGFR年斜率在托伐普坦组为2.4 ml/min per 1.73 m2,安慰剂组为-2.2 ml/min per 1.73 m2(P = 0.04);B阶段两组斜率分别为-1.3和-2.1 ml/min per 1.73 m2(P = 0.54)。
- 健康相关生活质量结局显示两阶段均保持高功能水平。
关键数值与推荐
- A阶段eGFR年斜率组间差异P = 0.04;B阶段eGFR年斜率组间差异P = 0.54。
- B阶段水利尿相关不良事件发生率既往安慰剂组48.7% vs 既往托伐普坦组14.3%;脱水相关28.2% vs 14.3%。
临床怎么用
- 对于快速进展风险的儿童ADPKD患者,托伐普坦治疗2年安全性和耐受性良好,肾功能稳定。
- 治疗第一年可能对延缓htTKV增长最为关键。
- 需关注水利尿和脱水相关不良事件,尤其从安慰剂转换为托伐普坦的患者。
局限性
- B阶段为开放标签扩展,无对照,结果需谨慎解读。
- 样本量较小(B阶段81例),长期结局需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tolvaptan is indicated for adults with autosomal dominant polycystic kidney disease (ADPKD) at increased risk of rapid progression. Pharmacodynamic activity and acceptable safety and tolerability were demonstrated in a 1-year, randomized, placebo-controlled trial in children and adolescents with ADPKD (Phase A of a 2-part, phase-3b study [NCT02964273]). Here, the 2-year, open-label extension (Phase B) is reported. METHODS: Phase A participants could enter Phase B if they had not experienced adverse events requiring discontinuation. All Phase B participants received tolvaptan, titrated based on body weight and tolerability. Outcomes included safety, tolerability, kidney function, height-adjusted total kidney volume (htTKV), and health-related quality of life (HRQoL). RESULTS: Of 84 Phase A completers, 81 enrolled in Phase B. No liver enzyme elevations observed in either phase met criteria for drug-induced liver injury. The previous placebo group experienced more aquaresis-related (48.7% vs. 14.3%) and dehydration-related (28.2% vs. 14.3%) adverse events than the previous tolvaptan group in Phase B. Tolerability was favorable, with HRQoL outcomes indicating high functioning in both the trial phases. Estimated glomerular filtration rate (eGFR) remained stable in the tolvaptan arm and decreased in the placebo arm of Phase A (annual slope in ml/min per 1.73 m2 of 2.4 and -2.2, respectively [P = 0.04]), with similar slopes of decline for both arms of Phase B (-1.3 in the prior tolvaptan arm and -2.1 in the prior placebo arm [P = 0.54]). htTKV growth was slowest during the first year of tolvaptan treatment. CONCLUSION: Tolvaptan-related safety and overall HRQoL remained favorable, and kidney function was stable in this 2-year extension. The slowest htTKV growth occurred during year 1 of tolvaptan treatment.
引用
- Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, et al. Clinical Trial of Tolvaptan in Pediatric ADPKD: Two-Year, Open-Label Extension. Kidney Int Rep. 2026. PMID: 42923342. doi:10.1016/j.ekir.2026.107077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。